Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.66 and traded as high as $0.9479. Brainstorm Cell Therapeutics shares last traded at $0.85, with a volume of 8,002 shares trading hands.

Brainstorm Cell Therapeutics Trading Down 9.5%

The firm has a market cap of $9.38 million, a price-to-earnings ratio of -0.25 and a beta of 0.48. The stock has a 50-day moving average of $0.72 and a two-hundred day moving average of $0.66.

Brainstorm Cell Therapeutics Company Profile

BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.

The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).